Davide Ciardiello, Medical Oncologist at Division of Gastrointestinal and Neuroendocrine Tumors at European Institute of Oncology, shared a post on LinkedIn:
“January 30 will be a date to remember for oncologists who deal with neoplasms of the gastrointestinal tract…
AIFA has just expressed a favourable opinion on the inclusion of the combination encorafenib+cetuximab and FOLFOX in the list established by Law no. 648/96.
The BREAKWATER study (Kopetz et al NEJM 2025) had shown that this combination is able to double the survival of patients with colorectal BRAFV600E mutated cancers compared to a standard therapy.
These are incredible results that demonstrate how a molecularly targeted therapy is able to transform the natural history of an extremely aggressive disease.
If this was also possible thanks to the request to AIFA carried out by the president of the Oncology Group of Southern Italy (GOIM) Roberto Bordonaro, by the past president Prof. Ferdinando De Vita and by the president-elect Prof. Fortunato Ciardiello.”
More posts featuring Davide Ciardiello on OncoDaily.